Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

2010277 citationsReview

Authors

Good health and well-being

Published in: Cancer Treatment Reviews

Volume 36, Issue 6, pp. 458-467

Field-Weighted Citation Impact: 9.16